+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Darbepoetin Alfa Market by Indication (Anemia In Hepatitis, Anemia In HIV, Chemotherapy Induced Anemia), End User (Clinics, Home Care, Hospitals), Route Of Administration, Distribution Channel, Dosage Form - Global Forecast 2025-2030- Product Image
Darbepoetin Alfa Market by Indication (Anemia In Hepatitis, Anemia In HIV, Chemotherapy Induced Anemia), End User (Clinics, Home Care, Hospitals), Route Of Administration, Distribution Channel, Dosage Form - Global Forecast 2025-2030- Product Image
Sale

Darbepoetin Alfa Market by Indication (Anemia In Hepatitis, Anemia In HIV, Chemotherapy Induced Anemia), End User (Clinics, Home Care, Hospitals), Route Of Administration, Distribution Channel, Dosage Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968192
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Darbepoetin Alfa Market is advancing steadily, shaped by evolving clinical needs, scientific innovation, and shifting commercial realities. Senior decision-makers are increasingly focused on optimizing anemia management strategies as complexities in care delivery, regulatory oversight, and international trade continue to intensify.

Market Snapshot: Darbepoetin Alfa Market Growth Trajectory

The Darbepoetin Alfa Market grew from USD 82.19 million in 2024 to USD 86.75 million in 2025. It is expected to continue growing at a CAGR of 5.34%, reaching USD 112.34 million by 2030. Key forces shaping this trend include increased adoption of erythropoiesis-stimulating agents, improvements in cold chain and distribution logistics, and a stronger emphasis on patient-centric care models. Recent technological and regulatory advances are altering market leadership and providing new opportunities for portfolio differentiation across geographies.

Scope & Segmentation

  • Indications: Anemia linked to hepatitis, HIV-related anemia, anemia induced by chemotherapy, chronic kidney disease-related anemia.
  • End Users: Clinics, home care providers, private hospitals, public hospitals.
  • Route of Administration: Intravenous (prefilled syringes; vials), subcutaneous (prefilled syringes; vials).
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy.
  • Dosage Forms: Cartridges, multiple dose vials, prefilled syringes.
  • Regions: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Technologies: Advanced protein engineering, biosimilar development, cold chain management, digital health tools for monitoring and patient adherence.
  • Leading Companies: Amgen Inc., Pfizer Inc., Sandoz International GmbH, Viatris Inc., Fresenius Kabi AG, Intas Pharmaceuticals Limited, Biocon Limited, Aspen Pharmacare Holdings Limited, STADA Arzneimittel AG, Celltrion Healthcare Co., Ltd.

Key Takeaways for Senior Decision-Makers

  • The market is driven by a shift toward multidisciplinary anemia management, with Darbepoetin alfa considered integral in both inpatient and outpatient settings.
  • Adoption of long-acting formulations and use of advanced dosing devices are reducing administration frequency, improving patient convenience and supporting adherence strategies.
  • Regulatory changes, including modified approval pathways for biosimilars, are accelerating competitive entries, requiring close monitoring of pipeline activity and intellectual property landscapes.
  • Regional dynamics necessitate tailored go-to-market strategies, factoring reimbursement structures, infrastructure maturity, and patient education outreach.
  • Investment in patient support programs, remote monitoring, and real-world data integration is distinguishing manufacturers in payer negotiations and clinical protocol inclusion.
  • Strategic collaborations between innovators and contract organizations are optimizing production scale and enabling rapid responses to local market fluctuations.

Tariff Impact on Darbepoetin Alfa Supply Chain and Market Access

Recent United States tariffs on biologic therapies have heightened supply chain complexity for Darbepoetin alfa. Manufacturers face increased import costs, prompting shifts in sourcing and logistics strategies. Distributors and providers are renegotiating contracts and revisiting reimbursement models to balance cost burdens with uninterrupted patient access. Scenario planning using predictive analytics is now standard for stakeholders intent on mitigating the impact of ongoing tariff and regulatory changes.

Methodology & Data Sources

This report employs a rigorous methodology, integrating primary interviews with industry experts and healthcare professionals, in-depth secondary data review, and triangulation across data streams to bolster reliability. Quality control includes peer review, supply chain consultations, and adherence to ethical research practices, ensuring insight accuracy and relevance for market leaders.

Why This Report Matters

  • It informs strategic investments and partnerships by analyzing how science, technology, regional policies, and competitive actions reshape anemia care delivery globally.
  • Decision-makers gain a granular view of market shifts, segmentation drivers, and emerging risks or opportunities, supporting resource optimization and long-term planning.
  • Actionable insights empower leaders to align innovation pipelines, operational tactics, and regional strategies for sustainable growth in the Darbepoetin Alfa Market.

Conclusion

The Darbepoetin Alfa Market is evolving rapidly, with regulatory, technological, and commercial transformation driving new standards in anemia management. Leaders equipped with timely, actionable intelligence will capitalize on emerging trends and position for ongoing success.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Biosimilar competition reshaping darbepoetin alfa market share and pricing dynamics
5.2. Adoption of novel subcutaneous delivery systems improving patient adherence rates
5.3. Emergence of hypoxia-inducible factor inhibitors as competitive alternatives in renal anemia management
5.4. Expansion of label indications for darbepoetin alfa in pediatric chronic kidney disease populations
5.5. Integration of real-world evidence into treatment guidelines for oncology-induced anemia management
5.6. Healthcare policy and reimbursement reforms influencing accessibility of erythropoiesis-stimulating agents
5.7. Manufacturing innovations and supply chain optimizations reducing cost of darbepoetin alfa production
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Darbepoetin Alfa Market, by Indication
8.1. Introduction
8.2. Anemia In Hepatitis
8.3. Anemia In HIV
8.4. Chemotherapy Induced Anemia
8.5. Chronic Kidney Disease Anemia
9. Darbepoetin Alfa Market, by End User
9.1. Introduction
9.2. Clinics
9.3. Home Care
9.4. Hospitals
9.4.1. Private Hospitals
9.4.2. Public Hospitals
10. Darbepoetin Alfa Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.2.1. Prefilled Syringes
10.2.2. Vials
10.3. Subcutaneous
10.3.1. Prefilled Syringes
10.3.2. Vials
11. Darbepoetin Alfa Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Darbepoetin Alfa Market, by Dosage Form
12.1. Introduction
12.2. Cartridge
12.3. Multiple Dose Vial
12.4. Prefilled Syringe
13. Americas Darbepoetin Alfa Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Darbepoetin Alfa Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Darbepoetin Alfa Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Pfizer Inc.
16.3.3. Sandoz International GmbH
16.3.4. Viatris Inc.
16.3.5. Fresenius Kabi AG
16.3.6. Intas Pharmaceuticals Limited
16.3.7. Biocon Limited
16.3.8. Aspen Pharmacare Holdings Limited
16.3.9. STADA Arzneimittel AG
16.3.10. Celltrion Healthcare Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DARBEPOETIN ALFA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DARBEPOETIN ALFA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DARBEPOETIN ALFA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DARBEPOETIN ALFA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DARBEPOETIN ALFA MARKET: RESEARCHAI
FIGURE 26. DARBEPOETIN ALFA MARKET: RESEARCHSTATISTICS
FIGURE 27. DARBEPOETIN ALFA MARKET: RESEARCHCONTACTS
FIGURE 28. DARBEPOETIN ALFA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DARBEPOETIN ALFA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DARBEPOETIN ALFA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DARBEPOETIN ALFA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ANEMIA IN HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ANEMIA IN HEPATITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ANEMIA IN HIV, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ANEMIA IN HIV, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CHEMOTHERAPY INDUCED ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CHEMOTHERAPY INDUCED ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CHRONIC KIDNEY DISEASE ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CHRONIC KIDNEY DISEASE ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CARTRIDGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY CARTRIDGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY MULTIPLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY MULTIPLE DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DARBEPOETIN ALFA MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES DARBEPOETIN ALFA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. CANADA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. CANADA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 108. CANADA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 109. CANADA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 112. CANADA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 113. CANADA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 114. CANADA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 115. CANADA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 118. CANADA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 119. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 130. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 131. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 134. MEXICO DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA DARBEPOETIN ALFA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 201. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 212. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 213. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 216. GERMANY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 217. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 228. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 229. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 232. FRANCE DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. ITALY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. ITALY DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. ITALY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. ITALY DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ITALY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. ITALY DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. ITALY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 258. ITALY DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 259. ITALY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 260. ITALY DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 261. ITALY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 264. ITALY DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 265. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 276. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 277. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 280. SPAIN DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 328. SOUTH AFRICA DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 329. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 334. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 335. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 336. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 337. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 338. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 339. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 340. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 341. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 342. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 343. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 344. DENMARK DARBEPOETIN ALFA MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 345. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 346. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 347. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 348. NETHERLANDS DARBEPOETIN ALFA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 349. NETHERLANDS DARBEPOETIN AL

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Darbepoetin Alfa market report include:
  • Amgen Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Viatris Inc.
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Limited
  • Biocon Limited
  • Aspen Pharmacare Holdings Limited
  • STADA Arzneimittel AG
  • Celltrion Healthcare Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 86.75 Million
Forecasted Market Value ( USD ) by 2030 $ 112.34 Million
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Darbepoetin Alfa (Aranesp) Market Report 2025 - Product Image

Darbepoetin Alfa (Aranesp) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Darbepoetin Alfa (Aranesp) Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Darbepoetin Alfa (Aranesp) Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Anemia Drugs Market by Drug Class (Erythropoiesis Stimulating Agents, Folic Acid And B12, Iron Supplements), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Route Of Administration, End User - Global Forecast 2025-2030 - Product Image

Anemia Drugs Market by Drug Class (Erythropoiesis Stimulating Agents, Folic Acid And B12, Iron Supplements), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Route Of Administration, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Chronic Kidney Disease Medication Market by Erythropoiesis Stimulating Agents, Phosphate Binders, Vitamin D Receptor Activators, Iron Supplements, Calcimimetics - Global Forecast 2025-2030 - Product Image

Chronic Kidney Disease Medication Market by Erythropoiesis Stimulating Agents, Phosphate Binders, Vitamin D Receptor Activators, Iron Supplements, Calcimimetics - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Epoetin Alfa Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Epoetin Alfa Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From

About the Market

Darbepoetin Alfa is a type of hematological drug used to treat anemia. It is a recombinant form of erythropoietin, a hormone produced naturally in the body that stimulates the production of red blood cells. Darbepoetin alfa is used to treat anemia caused by chronic kidney disease, chemotherapy, or HIV/AIDS. It is also used to reduce the need for red blood cell transfusions in patients with certain types of anemia. The Darbepoetin Alfa market is highly competitive, with a number of companies offering products. Some of the major players in the market include Amgen, Pfizer, Johnson & Johnson, Novartis, and Roche. These companies are engaged in research and development activities to develop new products and expand their product portfolios. They are also investing in marketing and promotional activities to increase their market share. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.